Corxel Pharmaceuticals closed a $287 million Series D to propel its oral small‑molecule GLP‑1 receptor agonist CX‑11 through ongoing U.S. phase II studies and planned global trials, and to prepare for phase III. The financing supports both obesity and type 2 diabetes development programs and signals investor appetite for oral agents in the GLP‑1 category. Corxel said proceeds will fund U.S. phase II completion, a global phase II in diabetes, and early phase III preparations, while advancing other cardiometabolic candidates. The company noted its headquarters in New Jersey with operations in Shanghai and emphasized plans to scale global development alongside regulatory planning.